AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01 Phase III trial, which focused on patients with advanced nonsquamous non-small cell lung cancer (NSCLC). The study, conducted in collaboration with Daiichi Sankyo, compared datopotamab deruxtecan with docetaxel, the standard chemotherapy, revealing a median overall survival (OS) […]
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan’s potential as a treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). This trial marks a significant milestone as datopotamab deruxtecan, a TROP2-directed antibody drug conjugate (ADC), showed a clinically meaningful improvement in overall survival (OS) compared to […]
The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that have an activating HER2 (ERBB2) mutation, following platinum-based chemotherapy treatment with or without immunotherapy. This significant decision is backed by the positive outcomes of the DESTINY-Lung02 phase 2 trial, […]
AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union (EU) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC). Specifically designed for tumors with an activating HER2 (ERBB2) mutation, the drug aims to fill a significant gap in systemic therapy options following platinum-based chemotherapy. Enhertu’s EU […]
The HERTHENA-Lung01 Phase 2 trial, presented at the 2023 World Conference on Lung Cancer by Daiichi Sankyo, demonstrated that Patritumab Deruxtecan has potential for treating EGFR-mutated metastatic non-small cell lung cancer (NSCLC). The drug revealed a confirmed objective response rate (ORR) of 29.8% in 225 patients, with a median progression-free survival of 5.5 months and […]
American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF). Despite a numerical improvement in certain outcomes, the study failed to achieve statistical significance for […]
The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with multiple HER2-expressing advanced solid tumours. These positive outcomes mark the successful achievement of two secondary endpoints of the trial. In the primary analysis, Enhertu […]
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in adult patients with unresectable or metastatic HER2-low breast cancer. The approval applies to patients who have undergone prior systemic therapy in a metastatic setting or experienced disease recurrence within six […]
Daiichi Sankyo and AstraZeneca have received the approval of the European Union (EU) for their jointly developed Enhertu (trastuzumab deruxtecan) for the treatment of a type of breast cancer patients. Enhertu has been approved as a monotherapy for the treatment of adult patients having unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast […]
Kite Pharma, a subsidiary of Gilead Sciences, and Daiichi Sankyo have received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for their Yescarta (axicabtagene ciloleucel) for initial treatment of relapsed/refractory large B-cell lymphoma (LBCL). Yescarta, a chimeric antigen receptor (CAR) T-cell therapy, is used only in patients who have not received a […]
